QPW
BCRX icon

Quantum Private Wealth’s BioCryst Pharmaceuticals BCRX Stock Holding History

Quantum Private Wealth’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$162K – 190
2022
Q1 		$162K Hold
10,000
– – 0.07% 187
2021
Q4 		$138K Buy
+10,000
New +$132K 0.05% 199

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quantum Private Wealth's BCRX Position: Q2 2022 in Review

Quantum Private Wealth sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 10,000 shares — an estimated $162K sold.

Quantum Private Wealth first reported a position in BCRX in Q4 2021 and held it in 2 quarters. The position peaked at $162K in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Quantum Private Wealth reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Quantum Private Wealth sold 10,000 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $162K.
  • Quantum Private Wealth first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Quantum Private Wealth's BioCryst Pharmaceuticals position peaked at $162K in Q1 2022.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Quantum Private Wealth's 13F filing for Q2 2022, filed 17 Aug 2022.